IKT Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 22:00):

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain...

Stats
Tagesvolumen	98 979.00
Durchschnittsvolumen	103 828
Marktkapitalisierung	11.08M
EPS	$0 ( 2024-03-29 )
Nächstes Ertragsdatum	( $-0.790 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.480
ATR14	$0.0260 (1.52%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Werner Milton H.	Buy	45 000	Stock Option (right to buy)
2024-04-01	Lees-rolfe Garth	Buy	90 000	Stock Option (right to buy)
2024-04-01	Lees-rolfe Garth	Sell	5 834	Stock Option (right to buy)
2023-06-30	Berman Dennis N	Buy	6 667	Stock Option (right to buy)
2023-06-30	Dion Gisele	Buy	6 667	Stock Option (right to buy)

INSIDER POWER
96.53
Last 62 transactions
Buy: 1 923 769 \| Sell: 2 120 717

Volumen Korrelation

Lang: -0.10 (neutral)

Kurz: -0.36 (neutral)

Signal:(46.053) Neutral

Inhibikase Therapeutics, Korrelation

10 Am meisten positiv korreliert
SVOK	0.82

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Inhibikase Therapeutics, Korrelation - Währung/Rohstoff

0.33
( neutral )

0.41
( neutral )

0.00
( neutral )

0.41
( neutral )

-0.10
( neutral )

-0.44
( neutral )

Inhibikase Therapeutics, Finanzdaten

Annual	2023
Umsatz:	$260 500
Bruttogewinn:	$83 102.00 (31.90 %)
EPS:	$-3.57

FY	2023
Umsatz:	$260 500
Bruttogewinn:	$83 102.00 (31.90 %)
EPS:	$-3.57

FY	2022
Umsatz:	$123 440
Bruttogewinn:	$116 717 (94.55 %)
EPS:	$-4.26

FY	2021
Umsatz:	$3.10M
Bruttogewinn:	$3.10M (100.00 %)
EPS:	$-0.810

Financial Reports:

No articles found.

Inhibikase Therapeutics,

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.